David Lee Johnson - Oct 1, 2021 Form 4 Insider Report for Global Blood Therapeutics, Inc. (GBT)

Role
Chief Commercial Officer
Signature
/s/ Miguel Carrillo, as Attorney-in-Fact
Stock symbol
GBT
Transactions as of
Oct 1, 2021
Transactions value $
-$56,963
Form type
4
Date filed
10/5/2021, 04:05 PM
Previous filing
Sep 3, 2021
Next filing
Feb 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Options Exercise +4.38K +11.87% 41.2K Oct 1, 2021 Direct F1
transaction GBT Common Stock Tax liability -$57K -2.17K -5.26% $26.25 39.1K Oct 1, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Options Exercise $0 -4.38K -50% $0.00 4.38K Oct 1, 2021 Common Stock 4.38K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2 Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs.
F3 The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.